Figure 3.

Mix culture assay results revealed that the combination of MEK and BCL-XL inhibitors effectively targeted all KRAS mutations. In all KRAS mutations, the combination of trametinib and ABT263 significantly reduced RPR when compared with drug-free controls. In addition, the RPR of trametinib in combination with ABT263 was significantly reduced in all KRAS mutation groups compared with trametinib administered alone. In all KRAS mutants, except for G13D, the RPR of trametinib combined with ABT263 was significantly reduced compared with ABT263 alone. ^*P<0.05 and ^**P<0.01. KRAS, Kirsten rat sarcoma 2 viral oncogene homolog; RPR, relative proliferation ratio; cont., control; n.s., not significant.